Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says

Kiran Mazumdar-Shaw of Biocon & Biocon Biologics discusses the company's acquisition of Viatris' biosimilars business and says Indian investors are "very wary" of overseas acquisitions and there was a "huge debt component."